Maze Therapeutics, Inc.
MAZE
$13.71
$0.403.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.82% | 27.44% | 7.19% | 19.10% | -0.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.34% | 26.37% | 28.96% | 5.95% | 1.23% |
| Operating Income | -126.14% | -26.37% | -28.96% | 3.96% | 655.20% |
| Income Before Tax | -123.92% | -0.90% | -12.33% | -1.15% | 673.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.22% | -0.90% | -11.30% | -0.02% | 666.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.22% | -0.90% | -11.30% | -0.02% | 666.52% |
| EBIT | -126.14% | -26.37% | -28.96% | 3.96% | 655.20% |
| EBITDA | -125.51% | -28.28% | -31.47% | 3.23% | 683.06% |
| EPS Basic | -112.99% | 21.44% | 82.43% | 90.66% | 154.58% |
| Normalized Basic EPS | -101.31% | 90.35% | -18.03% | 13.88% | 642.39% |
| EPS Diluted | -123.93% | 22.86% | 79.89% | 90.66% | 129.67% |
| Normalized Diluted EPS | -102.36% | 90.35% | -18.03% | 13.88% | 400.35% |
| Average Basic Shares Outstanding | 1,733.22% | 1,125.22% | 5.07% | 5.03% | 5.58% |
| Average Diluted Shares Outstanding | 915.14% | 1,125.22% | 5.07% | 5.03% | 90.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |